Clinical Research
Clinical Trials
Offering pulmonary vascular disease patients the latest in diagnostics, prevention, and treatment is at the forefront of the Vera Moulton Wall Center's mission. In addition to access to the latest large scale pharmaceutical trials, the Center is also conducting a number of smaller Stanford initiated trials. These trials, which are only available at Stanford, have been developed by Stanford researchers and are bringing the latest discoveries out of the laboratory and to the bedside.
The Center has anywhere from 5-10 studies actively recruiting patients most of the time. Studies range from investigating the safety and efficacy of new medications and evaluating combination therapies of FDA approved therapies to participating in database and biobanking projects.
Active PH Trials at Stanford
A Study to Learn About the Treatment LTP001 in Participants With PAH (Part B)
Brief Summary: The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension. We are only doing Part B at Stanford.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Active and recruiting
Advance Outcomes
Brief Summary: Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Active, not recruiting
Exposure to Substances in PAH: XPOSE-PAH
Brief Summary: The primary objective of this study is to see whether there is a link between the use of alcohol, tobacco,
marijuana, pain medications, and other substances and pulmonary arterial hypertension (PAH).
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Active and recruiting
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) (HARMONIZE)
Brief Summary: Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH that is caused by heart failure with preserved ejection fraction (HFpEF).
Researchers want to know if the study treatment, sotatercept, can treat people with Cpc-PH caused by HFpEF. This is an extension study, which means people who took part in a certain study on sotatercept for Cpc-PH (called a parent study) may be able to join this study. In this extension study, people will take sotatercept and researchers will follow their health for a longer time.
The main goal of this extension study is to learn about the long-term safety of sotatercept and if people tolerate it over a longer period of time.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Active, not recruiting
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Brief Summary: The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III. The secondary objective for this trial is to determine the effect of GB002 (seralutinib) on improving exercise capacity in this population.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Active, not recruiting
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Brief Summary: This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Enrolling by invitation
Pulmonary Hypertension Association Registry (PHAR)
Brief Summary: The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Recruiting
Advance Extension
Brief Summary: Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Principal Investigator: Roham Zamanian, MD, FCCP
Stanford Study Status: Enrolling by invitation
PH Patient Database Project
The Vera Moulton Wall Center has one of the largest academic pulmonary hypertension databases in the world. Developed almost 20 years ago it has served as the model for other large scale PH databases. In addition to standard demographic data, the database tracks patient visits, admissions, and more than 200 other data points from various tests and lab studies. Stanford PH patients simply need to sign an informed consent and agree to participate, no other visits or tests are needed beyond routine patient care.
This aggregate data allows researchers to look at the 'bigger picture' and look for trends and patterns among larger PH populations and also much smaller, very specific groups to better understand patterns and trends across groups of PH patients.
Stanford PH Biobank
Contact Us
To be considered for one of our trials please contact us to see if you are eligible.
Our studies include a wide range of patients, representing a diverse group of ages (including pediatrics), ethnicities and socioeconomic backgrounds. To learn about current trials or to be considered for future trials please contact us by email.